A Canadian R&D Leader

GlaxoSmithKline Inc. (GSK) is one of the largest research and development (R&D) organizations in Canada. GSK invested more than $112 million in Canadian research and development (R&D) in 2012, ranking it among the top 30 contributors to R&D in Canada, across all industries.

Research & Development

Clinical Studies

  • In 2012, GSK invested $40 million in conducting 58 clinical trials across Canada, and involving over 3,500 patients.
  • In 2012, GSK supported more than 40 Investigator Sponsored Studies with physicians across Canada.
  • In 2012, GSK sponsored approximately 23 local trials (health economics and outcomes research, phase IV) to support the scientific understanding of our medicines and vaccines in Canada.
Test Tubes

Global Product Pipeline

Building the best product pipeline in the industry

Pharmaceutical Development

The company's Pharmaceutical Development Division has developed a number of products including: Zofran® syrup and the fast-disintegrating Zofran® ODT tablets for nausea and vomiting associated with chemotherapy and radiotherapy treatments; and Heptovir® tablets for the treatment of hepatitis B.

Research & Development

The Pathfinders Fund

GlaxoSmithKline's $22 million Pathfinders Fund for Leaders in Canadian Health Science Research was established to help Canada become a world leader in R&D. This initiative encourages health science research and fosters medical innovation in Canadian medical schools.